[go: up one dir, main page]

MX2022005033A - Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta. - Google Patents

Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta.

Info

Publication number
MX2022005033A
MX2022005033A MX2022005033A MX2022005033A MX2022005033A MX 2022005033 A MX2022005033 A MX 2022005033A MX 2022005033 A MX2022005033 A MX 2022005033A MX 2022005033 A MX2022005033 A MX 2022005033A MX 2022005033 A MX2022005033 A MX 2022005033A
Authority
MX
Mexico
Prior art keywords
lymphocytes
antibody
differentiation
combined
group
Prior art date
Application number
MX2022005033A
Other languages
English (en)
Inventor
Rainer Boxhammer
Jan Endell
Dominik Pretscher
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2022005033A publication Critical patent/MX2022005033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción está dirigida a una terapia combinada que comprende un anticuerpo anti-CD19 o un fragmento de anticuerpo de este y linfocitos T gamma delta (linfocitos T ?d) para el uso en el tratamiento de leucemias o linfomas.
MX2022005033A 2019-10-31 2020-10-30 Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta. MX2022005033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19206479 2019-10-31
PCT/EP2020/080494 WO2021084063A1 (en) 2019-10-31 2020-10-30 Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells

Publications (1)

Publication Number Publication Date
MX2022005033A true MX2022005033A (es) 2022-09-09

Family

ID=68424789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005033A MX2022005033A (es) 2019-10-31 2020-10-30 Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta.

Country Status (16)

Country Link
US (1) US20210130461A1 (es)
EP (1) EP4051710B1 (es)
JP (2) JP7688025B2 (es)
KR (1) KR20220116154A (es)
CN (1) CN115151565A (es)
AU (1) AU2020372646A1 (es)
CA (1) CA3158984A1 (es)
DK (1) DK4051710T3 (es)
FI (1) FI4051710T3 (es)
IL (1) IL292213A (es)
MA (1) MA69251B1 (es)
MX (1) MX2022005033A (es)
PH (1) PH12022551009A1 (es)
SI (1) SI4051710T1 (es)
TW (1) TWI883067B (es)
WO (1) WO2021084063A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3337506T3 (da) 2015-08-21 2021-09-06 Morphosys Ag Kombinationer og anvendelser deraf
JP7094950B2 (ja) 2016-10-28 2022-07-04 モルフォシス・アーゲー 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR102617497B1 (ko) 2022-09-15 2023-12-27 주식회사 엘지에너지솔루션 음극용 자성 정렬 장치 및 이를 이용한 음극의 제조방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69839147T2 (de) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
KR20080032097A (ko) 2005-06-20 2008-04-14 메다렉스, 인코포레이티드 씨디19 항체 및 그의 용도
JP2009521912A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減された免疫原性を有する抗ｃｄ１９抗体
HRP20140331T1 (hr) * 2006-08-14 2014-05-09 Xencor, Inc. Optimizirana antitijela usmjerena na cd19
EP2066349B1 (en) 2006-09-08 2012-03-28 MedImmune, LLC Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
KR20110122859A (ko) 2009-02-23 2011-11-11 그렌마크 파머수티칼스 에스. 아. Ｃｄ１９에 결합하는 인간화된 항체 및 그것의 용도
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
US8940707B2 (en) 2010-10-28 2015-01-27 Viropharma Incorporated Maribavir isomers, compositions, methods of making and methods of using
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
ES2643387T3 (es) 2011-05-19 2017-11-22 Instituto De Medicina Molecular Estirpe celular de linfocitos que comprende células gama-delta, composición y método de producción de la misma
CA2951427A1 (en) * 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
DK3220926T3 (da) 2014-11-17 2025-03-24 Adicet Therapeutics Inc Konstruerede gamma-delta-t-celler
US10617691B2 (en) * 2015-05-26 2020-04-14 Morphosys Ag Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
EP3307875B1 (en) 2015-06-09 2021-12-15 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells
KR102821381B1 (ko) 2015-10-30 2025-06-13 캔써 리서치 테크놀로지 리미티드 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도
CN110072533B (zh) 2016-05-12 2024-04-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
MX2018016362A (es) 2016-06-27 2019-04-22 Morphosys Ag Formulaciones de anticuerpo anti-cd19.
CN110267678A (zh) * 2016-10-29 2019-09-20 霍夫曼-拉罗奇有限公司 抗mic抗体和使用方法
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途

Also Published As

Publication number Publication date
IL292213A (en) 2022-06-01
TW202131949A (zh) 2021-09-01
US20210130461A1 (en) 2021-05-06
TWI883067B (zh) 2025-05-11
PH12022551009A1 (en) 2023-03-20
KR20220116154A (ko) 2022-08-22
MA69251B1 (fr) 2025-12-31
WO2021084063A1 (en) 2021-05-06
CN115151565A (zh) 2022-10-04
AU2020372646A1 (en) 2022-05-12
SI4051710T1 (sl) 2026-01-30
JP7688025B2 (ja) 2025-06-03
DK4051710T3 (da) 2025-12-15
JP2022554324A (ja) 2022-12-28
FI4051710T3 (fi) 2026-01-12
EP4051710A1 (en) 2022-09-07
CA3158984A1 (en) 2021-05-06
JP2025134705A (ja) 2025-09-17
EP4051710B1 (en) 2025-11-26

Similar Documents

Publication Publication Date Title
MX2022005033A (es) Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta.
PH12021550553A1 (en) Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell
MX2019012032A (es) Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3).
CL2018000853A1 (es) Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer.
MX2021008267A (es) Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp.
EP4424364A3 (en) Methods of treating liver disease
ZA201808537B (en) Combination therapies
BR112017009440A2 (pt) uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd)
CA3060516A1 (en) Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
BR112021012056A2 (pt) Inibidor da expressão gênica do hbv, agente que reduz a carga antigênica de hbv, composições para uso no tratamento de uma infecção crônica por hbv, usos de um inibidor da expressão gênica do hbv e de um agente que reduz a carga antigênica de hbv, métodos de tratamento da infecção crônica por hbv e kit
DOP2020000212A (es) ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS
MX390955B (es) Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma.
CO2022014388A2 (es) Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
EP3888648A4 (en) TREATMENT OF CANCER BY COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND FOLFIRINOX THERAPY
CH458843A (de) Vorrichtung zur Isolation gegen Stösse und Erschütterungen
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
ZA202102020B (en) Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
MX2022005031A (es) Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas.
CL2021000531A1 (es) Métodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
CO2021007006A2 (es) Moduladores de la expresión de irf5
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
ES2055314T3 (es) Tratamiento de disfuncion leucocitaria con gm-csf.
CL2020001429A1 (es) Tratamiento del vsr con producto combinado.